Evotaz

Evotaz is a fixed-dose combination tablet containing 300mg of atazanavir and 150mg of cobicistat.

Atazanavir is an HIV protease inhibitor. Cobicistat is used to boost blood levels of atazanavir and has no antiviral activity of its own. These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses. Evotaz received marketing approval in the United States in January 2015 and in the European Union in July 2015.

The standard dose of Evotaz is one pink tablet taken once daily with food. Evotaz is approved for use in combination with two or more other antiretroviral drugs. Evotaz should not be initiated in patients with creatinine clearance less than 70 ml/min if any co-administered agent (e.g. emtricitabine, lamivudine, tenofovir disoproxil fumarate) requires dose adjustment based on creatinine clearance.

The use of cobicistat to boost blood levels of atazanavir means that drug interactions with other medications are somewhat different from those reported for atazanavir, due to the potential for interactions between both cobicistat and boosted atazanavir and other medications.

Evotaz should not be used in combination with HIV protease inhibitors or non-nucleoside reverse transcriptase inhibitors with the exception of rilpivirine. Evotaz should not be used with proton pump inhibitors and if taken with tenofovir, it should not be used with H2 receptor antagonists (e.g. famotidine). In people not taking tenofovir, Evotaz and famotidine should be taken together, with food, or at least ten hours apart.

Use of the following medicines is also contraindicated with Evotaz:

  • Simeprevir
  • Clarithromycin (unless no alternative)
  • Voriconazole
  • Colchicine in patients with renal or hepatic impairment
  • Rifabutin
  • Rifampicin
  • Alfuzosin
  • Anti-epileptic drugs
  • Antipsychotics
  • Amiodarone
  • Dronedarone
  • Quinidine
  • Systemic lidocaine
  • Bepredil
  • Bosentan
  • Fluticasone propionate
  • St John’s wort
  • Hormonal contraceptives oestrogen and progestin
  • Simvastatin, atorvastatin, lovastatin
  • Salemeterol
  • Ergot derivatives
  • Midazolam
  • Triazolam
  • Cisapride
  • Warfarin
  • Rivaroxaban

Refer to the entry on atazanavir for further information on potential drug interactions, efficacy and drug resistance.

Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.